Brain cell development stalls in depression patients, study finds

Depression may be linked to a stalled development of new nerve cells in the adult brain, according to a new study published in Nature Medicine.

Researchers at Columbia University's medical school analyzed approximately 500,000 hippocampal cells from depressed adults and a control group. Using single-cell analysis, they observed that in depressed individuals, a significant number of cells remained in the early stem cell stage, with fewer progressing to the next stage of neuronal development. This suggests that while the initial cells for new neurons exist, their maturation process is hindered.

The study also found increased expression of genes related to stress response and immune signaling, such as interferon, particularly in patients who had experienced severe stress in the six months prior to their death. These molecular changes may contribute to the cognitive and emotional symptoms associated with depression.

This stalled neurogenesis could impact the hippocampus, a brain region crucial for memory and emotional processing. The hippocampus plays a role in "pattern separation," helping to differentiate between similar experiences and store them as distinct memories. When this function is impaired, neutral situations might be misinterpreted through the lens of past negative experiences, leading to persistent negative thoughts.

Furthermore, the research identified overactivation of specific neural populations involved in pain and stress regulation in depressed patients. This finding could explain why individuals with depression often report not only psychological distress but also physical pain, such as headaches and body aches. The study offers a cellular and molecular basis for understanding depression, suggesting that classifying the disorder based on these biological characteristics could pave the way for new treatment approaches.

“

As we have developed treatments by reclassifying cancer based on cell characteristics, depression could also be precisely reclassified based on molecular features, leading to the development of new treatments.